Valbiotis Stock
Price
Target price
€0.68
€0.68
0.150%
0.001
0.150%
-
04.12.25 / Frankfurt
WKN: A2DS5F / Name: Valbiotis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Valbiotis Stock
The Valbiotis stock is trending slightly upwards today, with an increase of €0.001 (0.150%) compared to yesterday's price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Valbiotis stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Valbiotis in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Valbiotis vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Valbiotis | 0.150% | - | - | - | - | - | - |
| Cerenis Therapeutics Holding S.A. | -1.570% | -7.457% | -2.323% | - | - | - | - |
| Genoway S.A. Inh. | -1.580% | 1.220% | -4.231% | -32.703% | -31.215% | -38.060% | -15.878% |
| Sensorion SA | -5.460% | -6.734% | -13.438% | -58.283% | -53.679% | -24.626% | -81.284% |
News
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue entirely dedicated to supporting the commercial expansion of its offering of dietary supplements